Drugmaker Akorn (AKRX) acquired rights to three eye-drop brands from Merck (MRK) division Inspire Pharmaceuticals Friday, sending Akorn stock to a new high in midday trading on the market. Akorn paid $52.8 million for two variants of glaucoma treatment Cosopt, along with AzaSite for bacterial conjunctivitis. The move added to Akorn’s strategy to become a top player in ophthalmology, which fueled its decision to buy Hi-Tech Pharmacal earlier this
View original post here:
Akorn Acquires Eye Drugs From Merck; Stock Hits High